Previous Research

A randomised, double-blind, placebo-controlled, phase II clinical trial with a cross-over design assessing efficacy of a single dose of bumetanide in reducing focal attack severity in hypokalaemic periodic paralysis (HypoPP) assessed using the McManis protocol.

A Phase II Randomised, Double-Blind, Placebo controlled, Cross-Over Study to Investigate the Efficacy of Mexiletine in Patients with Non-Dystrophic Myotonia.

Double-blind, placebo-controlled, parallel group, phase III study comparing dichlorphenamide vs. placebo for the treatment of periodic paralysis

Genotype - phenotype correlation and longitudinal studies in Andersen-Tawil syndrome

Genotype - phenotype correlation and longitudinal studies in Non-dystrophic Myotonias.